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Abstract
Purpose Early prosthetic joint infection (PJI) can be
treated with an intensive surgical debridement and implant
retention (DAIR) of the prosthesis if (1) the prosthesis is
stable, (2) the pathogen is not a difficult-to-treat microor-
ganism, (3) symptoms have lasted for \3 weeks and (4) a
sinus tract is absent.
Methods We retrospectively evaluated the treatment
outcome of early PJI in the hip and knee in a single
orthopaedic centre. An early PJI was defined as a prosthesis
infection within 3 months after primary implantation or
revision surgery for a non-infectious cause.
Results We identified 69 patients with confirmed early
PJI, with a median age of 71 (range 33–84) years. Only
64 % presented with C2 acute signs of infection. The most
commonly isolated bacteria were coagulase-negative
staphylococci (38 %) and Staphylococcus aureus (25 %).
Surgical procedures included DAIR (50 cases, 69 %) and
two-stage exchange (19 cases, 31 %). At last follow-up,
five of remaining living 67 patients (7.5 %) had a relapse
of infection. The overall relapse-free survival of the pros-
thesis after 2 years was 92.3 % (95 % confidence interval
82–97 %) with no significant difference between DAIR
and exchange of prosthesis.
Conclusion Our data suggest that an early PJI should be
treated with DAIR as a less invasive procedure whenever
possible according to the established treatment algorithm.
Keywords Early prosthetic joint infection  Implant
retention  Treatment outcome  Biofilm  Two-stage
exchange
Introduction
A periprosthetic joint infection (PJI) is a medical problem
that is becoming increasingly important worldwide due to
the increased usage of artificial joints [1]. PJI can be caused
by direct inoculation of bacteria to the implant or by hae-
matogenous seeding [2]. In the former case, bacteria from
the commensal skin flora around the surgical site or from
contamination by the healthcare provider are introduced to
the implant during or soon after surgery. The widest
accepted classification of PJI, proposed by a group from the
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Mayo Clinic, distinguishes between a stage 1 (or early), in
which the infection occurs in the first 3 months after sur-
gery, a stage two (or delayed), in which the infection occurs
between 3 and 24 months after surgery and typically has a
more indolent presentation with a pain-free interval, and a
stage three (or late), which includes infections that occur
after 2 years and which are frequently caused by haemat-
ogenous dissemination of microbial pathogens [3, 4]. Based
on this classification, in 2004 Zimmerli et al. [2] proposed an
individual treatment algorithm for each stage to attain a high
success rate with the least invasive surgical procedure.
Briefly, a delayed infection always needs an exchange of the
prosthesis, whereas early (onset \3 months postoperative)
or haematogenous infection can be cured by debridement
and retention of the prosthesis provided that (1) the pros-
thesis is stable, (2) the duration of symptoms does not
exceed 3 weeks, (3) there is intact skin and soft tissue and
(4) the causative pathogen is susceptible to a biofilm-active
antibiotic [2].
More recently, there has been intensive discussion on
the optimum period of time after surgery that defines an
early infection, with the definitions ranging between
2 weeks and 3 months [2, 3, 5–7]. In addition, there is a
wide range in the definition of the maximum length of time
(between 8 and 30 days) that clinical signs and symptoms
may present after which a debridement and retention
(DAIR) approach may still lead to a successful outcome [8,
9]. In the recently published Infectious Diseases Society of
America (IDSA) guidelines by Osmon et al. [7] a DAIR
strategy is recommended (evidence grade 2A) if infectious
symptoms occur early, i.e. within 30 days postoperatively,
or if the length of symptoms is \3 weeks. In the study
reported here, we retrospectively analysed the character-
istics and outcome of early PJI in a 5-year cohort of hip and
knee arthroplasties in a single centre. Since our centre
defined an early PJI as occurring within the first 3 months
postoperatively [2], we had the opportunity to investigate if
there was any difference in outcome after DAIR if the
definition of an early PJI was shortened from 3 months to
1 month. We speculated that patients with an early PJI
present not only with typical acute inflammatory signs and
symptoms. We also attempted to determine whether there
was a difference in the clinical outcome of PJI if the signs
and symptoms lasted longer than 3 weeks before a surgical
procedure was performed.
Materials and methods
Study design and population
The Schulthess Clinic Zurich is a specialized 160-bed
orthopaedic centre with a high rate of surgical interventions
(7,491 inpatient and 1,221 outpatient treatments docu-
mented in 2012; 804 primary hip and 579 knee arthropla-
sties). We retrospectively reviewed all early types of
infection after a knee or hip prosthesis implantation (either
after primary arthroplasty or revision surgery) presenting in
the Schulthess Clinic between January 2005 and June 2010.
Clinical information on infection was retrieved from the
prospectively managed database on all PJI from the
Infectious Diseases Clinical Consulting Service and from
the hospital information system managed by the Schulthess
Clinic in Zurich. Patients with a delayed infection (onset of
symptoms 3–24 months after the last surgery) as well as
patients with an incomplete follow-up were excluded.
Definitions
Prosthetic joint infection was diagnosed if one or more of
the following criteria were fulfilled: (1) visible purulence of
a preoperative aspirate or intraoperative periprosthetic tissue
(as determined by the surgeon); (2) presence of a sinus tract
communicating with the prosthesis; (3) microbial growth in
a preoperative joint aspirate, intraoperative periprosthetic
tissue or sonication fluid of the removed implant [2, 7]. We
defined a very early PJI as a prosthesis infection with
symptom onset B1 month after primary or revision surgery
of the knee or hip prosthesis [2] and an early manifestation
at C1 and B3 months. In the case of a non-healing wound
discharge postoperatively, we defined the onset of symptoms
14 days after the surgical operation. If an infection was
diagnosed with a revision surgery due to wound discharge or
postoperative hematoma within 14 days, the date of the
revision operation was defined as the onset of symptoms.
Patients with PJI symptoms were defined as those with
C2 and\2 typical acute inflammatory signs (such as pain,
purulent wound discharge, erythema, swelling/induration
or warmth of the joint, optionally fever), respectively, and
by chronic symptoms, such as sinus tract, or other non-
specific signs, such as hematoma, joint effusion or luxation
or elevated inflammatory serum biomarker only.
Surgical and antibiotic treatment of early infection
The surgical approach was individually determined at the
surgeon’s discretion in discussion with the Infectious
Disease Consulting Service. There were mainly three
potential approaches: (1) DAIR; (2) one- or two-stage
exchange of the implant; (3) resection arthroplasty. If only
parts of the prosthesis were removed, we considered the
surgical procedure to be a DAIR. For the best outcome with
a DAIR, orthopaedic surgeons always went for an
arthrotomy instead of for an arthoscopy for a better
infection control and for cultivating bacteria originating
from biofilm and not planktonic bacteria. During the study
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period, exchange of all mobile parts, type of lavage and
second-look surgeries were individually determined at the
surgeon’s discretion.
The duration of the antibiotic treatment was planned
either for 3 months, in the case of patients with hip pros-
thesis, or for 6 months, for patients with knee arthroplasty,
as recommended in guidelines [7]. An initial intravenous
therapy of at least 14 days was planned [2, 7].
Outcome evaluation
Follow-up visits were performed at the Outpatient Depart-
ment of Schulthess Clinic. The patients were followed up for
relapse of infection, new infection or death. We defined a
relapse of infection if: (1) the signs and symptoms of a per-
sistent infection (i.e. communicating sinus tract with the
prosthesis) were present after 21 days of an adequate surgical
and antibiotic treatment, and/or (2) the same pathogen either
as a monobacterial or polymicrobial infection was re-isolated
within 2 years after infection diagnosis and/or (3) if death
was directly related to the PJI diagnosis [10–13]. Cases of
death were allocated to be infection or non-infection rela-
ted. Patients who died early due to the sequelae of a sepsis
(e.g. pneumonia) or late to any illness were not defined as
relapses. A revision operation within 21 days after the first
therapeutic surgical procedure was not considered to be a
relapse. The most invasive surgical approach was reported as
the definitive surgical treatment. A new infection was defined
as a PJI at the same anatomical site upon the isolation of a
different microbial pathogen. Successful response was pos-
tulated if the patient had no signs and symptoms of relapse
and was not receiving suppressive antibiotic treatment after a
follow-up period of at least 24 months.
Statistical analysis
GraphPad Prism 6 software (GraphPad, San Diego, CA) was
used for the statistical calculations and for the construction of
figures. The probability of relapse-free survival and the 95 %
confidence interval (95 % CI) was estimated using the Kap-
lan–Meier survival method. Cox proportional hazard analysis
was used for the comparison of relapse-free survivals of dif-
ferent surgical subgroups. Observations were censored at the
time of diagnosis of infection relapse. Categorical variables
were compared by the chi-square test or Fisher’s exact test.
Results
Baseline characteristics
Between January 2005 and June 2010, 864 patients with a
possible PJI of the knee (n = 456) or hips (n = 408) treated
at the Schulthess Clinic in Zurich were documented in the
databank of the Infectious Disease Service. Of these, 75
(8.7 %) patients presented with symptoms of PJI in the early
postoperative period within 3 months after surgery. Six
patients were excluded because of an incomplete follow-up,
leaving 69 early infections for further analysis (28 knee, 41
hip prostheses). Characteristics of all 69 patients are sum-
marized in Table 1. The left side of the hip or knee joint was
more affected by an early infection (60.9 vs. 39.1 %).
Symptoms
The median time between the last surgical procedure and
onset of symptoms of infection was 14 days, and until
diagnostic and therapeutic surgical intervention for infec-
tion 22 days (Table 2). Of the 69 cases, the first symptoms
of infection manifested within 30 days in 58 cases (84 %)
and between 30 and 90 days in 11 cases (16 %). In 60
(87 %), the symptoms lasted \3 weeks until a diagnostic
and therapeutic surgical revision for infection was
performed.
Table 1 Baseline characteristics of 69 patients with an early peri-
prosthetic joint infection
Baseline characteristics n (%)a
Median age, years (range) 71 (33–84)
Females 34 (49.3)
Primary implantation of the prosthesis
Schulthess Clinic 55 (79.7)
External hospital 14 (20.3)
Last surgical procedure before infection
Primary implantation 37 (53.6)
Revision surgery 32 (46.4)
1 19
C2 13
Localization of joint prosthesis
Knee 28 (40.6)
Hip 41 (59.4)
Underlying joint disorder
Degenerative 58 (84)
Posttraumatic 6 (8.7)
Rheumatoid arthritis 4 (5.8)
Osteosarcoma 1 (1.4)
Comorbidity
Diabetes mellitus 10 (14.5)
Obesity 20 (29.0)
Neoplasia 5 (7.2)
Immunosuppression 12 (17.4)
There were 28 cases of PJI of the knee and 41 cases of PJI of the hip
a Data are presented as a number with the percentage given in
parenthesis, unless indicated otherwise
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Forty-four patients (64 %) showed C2 typical acute
inflammatory symptoms, such as pain, erythema, wound
discharge, swelling/induration or local warmth of the joint
(Tables 2, 3). Fifteen of these patients also developed
fever, of whom ten had positive blood cultures and two
died due to sepsis. Twelve patients (17 %) had only one
documented inflammatory sign of infection, and signs of a
chronic infection, such as the sinus tract, were documented
in five patients. In eight patients, non-inflammatory signs
and symptoms, such as haematoma, joint effusion or lux-
ation or elevated inflammatory serum biomarker, were the
only leading symptoms of the infection.
Diagnostic procedure
In the majority (67 of 69) of patients, microbial growth was
detected preoperatively and/or intraoperatively. The two
patients with culture-negative PJI showed highly infection-
suspicious intraoperative signs according to the orthopae-
dic surgeon, but were treated with antibiotics for 3 and
20 days, respectively. The mean number of intraopera-
tively retrieved tissue biopsies was 5.6 (range 2–11) in
order to facilitate the differentiation between the causal
pathogenic organism and contaminants. The most com-
monly isolated microorganisms were S. aureus (17, 38 %)
and coagulase-negative staphylococci (26, 25 %) with
methicillin resistance in one of 17 (6 %) and 24 of 26
(92 %) strains, respectively (Table 3). Many virulent
microorganisms, such as Staphylococcus aureus, Strepto-
coccus pyogenes, S. agalactiae, S. dysgalactiae subsp.
equisimilis or Bacillus cereus, presented with acute clinical
manifestation, whereas many patients with low-virulent
pathogens, such as coagulase-negative staphylococci,
Enterococcus faecalis or Propionibacterium acnes pre-
sented with delayed (sinus tract) or nonspecific symptoms
(Table 3).
Antibiotic treatment
The median duration of antibiotic treatment was 3.1 and
6.1 months for hip and knee PJI, respectively (Table 2),
calculated for all patients, including the two cases of
early death due to sepsis at day 9 and 27, respectively.
Initial intravenous therapy was performed for at least
14 days in 56 of 69 cases (81 %). Antimicrobial treat-
ment was chosen according to susceptibility testing of
the pathogen with an initial empirical treatment con-
sisting of an intravenous broad-spectrum beta-lactam
antibiotic in combination with rifampin. In two patients
with a culture-negative PJI, the intravenous empirical
treatment was followed by an oral treatment with a
fluoroquinolone (ciprofloxacin or levofloxacin) and
rifampin. In patients with a Staphylococcus species or
Propionibacterium acnes PJI, a rifampin-combination
regime was given as a potent antimicrobial substance
against bacteria in the biofilm [14, 15]. The infectious
diseases consultant chose the combination antimicrobial
Table 2 Characteristics of the 69 cases with early periprosthetic joint
infection
Characteristics n (%)a
Pathogenesis
Perioperatively acquired (exogenous) 62 (89.9)
Hematogenous 7 (11.1)
Time to manifestation of symptoms (days), median (range)
Last surgical intervention to onset of symptoms 14 (2–68)
Very early presentation (B1 month) 58 (84)
Early presentation ([1 month to B3 months) 11 (16)
Last surgical intervention to infection diagnosis 22 (2 – 92)
Length of symptoms B3 weeks 60 (87)
Length of symptoms [3 weeks 9 (13)
Duration of symptoms until surgical management of
infection
5 (0–78)
Symptoms, n (%)
C2 inflammatory signs and symptomsb 44 (64)
? fever 15
\2 inflammatory signs and symptoms 12 (17)
Wound dehiscence or discharge only 8
Persistent pain only 3
Warmth only 1
Sinus tract 5 (7)
Other signs and symptoms 8 (12)
Hematoma 3
Joint effusion 2
Joint luxation 2
Elevated inflammatory biomarker only 1
Antibiotic treatment, median months (range) 3.5 (0.3–8.3)
Intravenous (days) 17 (7–126)
Knee, median month (range) 6.1 (1.3–8.3)
Hip, median month (range) 3.1 (0.3–6.7)
Surgical treatment, n (%)
DAIR 50 (72.5)
? exchange of polyethylene inlay 17
? exchange of a part of the prosthesis 9
Two-stage exchange of the prosthesis 19 (27.5)
As the initial surgical approach 12
Within 20 days after initial DAIR 7
DAIR Debridement and implant retention, PJI periprosthetic joint
infection
There were 28 cases of PJI of the knee and 41 cases of PJI of the hip
a Data are presented as a number with the percentage given in
parenthesis, unless indicated otherwise
b C2 manifestations of inflammation, such as pain, purulent wound
discharge, erythema, swelling/induration and/or warmth of the joint
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drug according to antimicrobial susceptibility testing
(preferably a fluoroquinolone) to avoid the emergence of
rifampin resistance [16].
Surgical treatment
In the majority of patients (n = 50, 72.5 %), DAIR of the
prosthesis as the most invasive procedure was performed.
In 15 of these 50 patients (30 %), a second-look operation
with a repeated DAIR was performed within 2–18 (median
6) days due to haematoma (n = 1), wound discharge
(n = 10) or as routine (n = 4). In all but one DAIR (S.
aureus, intervention at day 6), intraoperative tissue biop-
sies at the second-look operation were negative. These
cases with repeated DAIR were not interpreted as treatment
failure because the intervention was carried out within
21 days after the initial surgical process.
A complete two-stage exchange of the prosthesis was
chosen in 19 patients (27.5 %); in seven of these patients
this exchange occurred within 20 days of the initial DAIR
(median 14, range 6–20 days). The reason for an exchange
were (1) symptoms lasting for [3 weeks (n = 4), (2)
diagnosis of a rifampin-resistant Staphylococcus (n = 1),
(3) hepatopathy with intolerance to rifampin in the case of
a staphylococcal PJI (n = 1) or (4) severely damaged
periprosthetic tissue (n = 13). No resection arthroplasty or
one-stage exchange of the prosthesis was performed. In the
case of a two-stage prosthetic exchange, the median time
between removal and replacement was 3.4 (range 0.5–14.9)
months.
Table 3 Microbiological characteristics with a description of the signs and symptoms of 69 patients with early periprosthetic joint infection
Microbial pathogen Symptoms/signs of PJI
Type of early PJI infection n (%) C2 inflammatory
signs/symptomsa
? fever \2 inflammatory
signs/symptoms
Sinus
tract
Other signs/
symptomsb
Monobacterial 64 (92.7) 44 (64 %) 15 12 (17 %) 5 (7 %) 8 (12 %)
Staphylococcus aureusc 17 16 6 1 0 0
Coagulase-negative staphylococcid 26 13 0 7 2 4
Streptococcus pyogenes 1 1 0 0 0 0
Streptococcus dysgalactiae subsp. equisimilis 1 1 1 0 0 0
Streptococcus agalactiae 2 2 1 0 0 0
Enterococcus faecalis 1 0 0 0 1 0
Bacillus cereus 1 1 1 0 0 0
Escherichia colie 3 2 1 1 0 0
Citrobacter koserie 2 1 0 1 0 0
Pseudomonas aeruginosae 1 0 0 0 0 1
Enterobacter cloacaee 1 1 1 0 0 0
Haemophilus parainfluenzac 1 0 1 0 0 1
Proteus mirabilise 1 1 0 0 0 0
Propionibacterium acnes 3 1 0 1 0 1
Granulicatella adjacens 1 0 1 1 0 0
Clostridium hastiformis 1 0 1 0 1 0
Candida famata 1 0 0 0 1 0
Polymicrobialf 3 (4.4) 2 0 0 0 1
Culture negative 2 (2.9) 2 1 0 0 0
a C2 manifestation of inflammation, such as pain, purulent wound discharge, erythema, swelling/induration or warmth of the joint haematoma,
joint effusion or luxation, elevated inflammatory serum biomarker only
b Haematoma, joint effusion or luxation, elevated inflammatory serum biomarker only
c Susceptibility testing: n = 16 methicillin susceptible, n = 1 methicillin resistant
d Coagulase-negative staphylococci included Staphylococcus epidermidis (n = 22), S. haemolyticus (n = 2), S. capitis (n = 2); n = 24
methicillin resistant, n = 2 methicillin susceptible
e No multidrug-resistant Gram-negative pathogens
f Polymicrobial infections included: S epidermidis, Propionibacterium acnes (n = 1); Proteus mirabilis, S. aureus, Enterococcus faecalis
(n = 1); S. epidermidis, E. faecalis (n = 1)
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Outcome analysis
Two patients died due to sequelae of sepsis caused by S.
epidermidis at day 9 and day 27 postoperatively, respec-
tively. At last follow-up, 62 of the 67 remaining patients
were free of infection (median 3.1 years, range
0.2–6.5 years) and five had a relapse of infection (median
time to relapse 0.6 years, range 0.2–0.9 years) with isola-
tion of the same microorganism (n = 3) or a persistent
wound discharge or sinus tract[3 weeks under continuous
antibiotic treatment (n = 2) (Table 4). Causing pathogens
were methicillin-resistant Staphylococcus epidermidis
(n = 3), methicillin-susceptible S. aureus (n = 1) and one
mixed infection with isolation of Proteus mirabilis and
Enterococcus faecalis. Two patients died 4 and 11 months
after surgery, respectively, due to a non-infectious reason.
In seven cases (11.1 %), a new infection with another
microorganism was documented.
The relapse-free survival of the prosthesis in 67 patients
(69 minus 2 deaths due to sequela of sepsis) was 92.3 %
(95 % CI 82.6–97 %) after 2 years (Fig. 1a). Stratified by
surgical procedure, the relapse-free survival of the pros-
thesis was 91.6 % (95 % CI 79.2–96.8) for debridement
with retention of the prosthesis and 94.2 % (95 % CI
65–99.2 %) for exchange of the prosthesis (Fig. 1b) after
2 years.
Outcome stratified according to time of manifestation
of infection
Of the 69 patients, 58 (84 %) and 11 (16 %) developed
signs of symptoms of infection within 30 days after surgery
(very early) and between 30 and 90 days (early), respec-
tively. All five relapses occurred in the group with very
early manifestation of clinical symptoms (four relapses
after DAIR, one relapse after a two-stage exchange of
prosthesis). Among the patients treated with debridement
and retention of the prosthesis, no significant difference in
cure rate was calculated for patients with onset of symp-
toms at less than or more than 30 days after the last surgery
(Fischer’s exact test P = 1).
Outcome stratified according to duration of symptoms
Recently published expert recommendations and guide-
lines (evidence grade 2A) recommend treating a PJI with
a DAIR if signs and symptoms have lasted \3 weeks [2,
7, 17]. Among our 69 patients, nine patients (13 %)
showed clinical symptoms for [3 weeks until a diag-
nostic and therapeutic intervention was performed. Of
these nine patients, four (44 %) were finally treated with
a two-stage exchange, five were treated with DAIR of
the prosthesis and two (one treated with DAIR and one
Table 4 Relapse of early periprosthetic joint infection
No. Age,
years
(sex)
Joint Infecting organism Time after
last
surgery
(months)
Durations
of
symptoms
(days)
Surgical
treatment
Antimicrobial treatment (total
duration of treatment)
Time to
relapse
(months)
1 67
(F)
Hip Staphylococcus epidermidis
(MR)
0.5 1 DAIR Amoxicillin-clavulanate iv,
trimethoprim-
sulfamethoxazole po
(suppression)
3.1 during
suppression
medication
2 76
(F)
Hip Staphylococcus epidermidis
(MR)
0.8 1 DAIR,
exchange of
part of
prosthesis
Vancomycin iv/R po,
fusidic acid po/R po
(3.6 months)
11.8
3 64
(M)
Knee Polymicrobial (Proteus
mirabilis, Enterococcus
faecalis, Staphylococcus
aureus) (MR)
0.4 1 DAIR Imipenem-cilastin iv/R po,
amoxicillin-clavulanate iv/R
po, ciprofloxacin po/R po
(6.1 months)
6.7
4 51
(F)
Hip Staphylococcus aureus
(MS)
0.3 44 DAIR. Bone
sequester
in situ
Flucloxacillin iv/R po,
levofloxacin po/R po
(4.5 months)
6.6
5 76
(F)
Hip Staphylococcus epidermidis
(MR)
0.9 12 Two-stage
exchange,
screw
remained
in situ
Daptomycin iv/R po, linezolid
po/R po, trimethoprim-
sulfamethoxazole po
(suppression)
1.8 during
suppression
There were 5 cases of relapse of PJI
R Rifampicin, MR methicillin resistant, MS methicillin sensitive, iv intravenous, po peroral, F female, M male
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with two-stage exchange) developed a relapse of infec-
tion. The possible reason for these relapses might have
been a persistent biofilm infection due to a remaining
screw after complete exchange of the prosthesis and a
remaining bone sequester after DAIR.
Among all 60 patients with symptoms less than 3
weeks, 45 and five were finally treated with DAIR and
two-stage exchange, respectively. Three patients devel-
oped a relapse of infection after DAIR. There was no
significant difference in cure rates according to duration
of symptoms of \3 or [3 weeks (Fisher’s exact test
P = 0.4).
Discussion
Our retrospective analysis of 69 early infections after
implantation of a knee or hip prosthesis shows that only
64 % of the patients presented with C2 acute inflammatory
symptoms. Staphylococcus aureus (25 %), coagulase-neg-
ative staphylococci (38 %) and Gram-negative bacteria
(11.6 %) were the most commonly found causative
microorganisms in early PJI, indicating that low virulent
pathogens, such as coagulase-negative staphylococci, quite
commonly cause early infection.
Two-thirds of the patients with early PJI showed C2
acute symptoms of an infection, such as pain, wound dis-
charge, erythema, swelling/induration or warmth of the
joint and/or fever. About one-third presented with only one
acute inflammatory symptom, with signs of a chronic
infection (sinus tract), or haematoma, joint effusion/luxa-
tion or elevated inflammatory serum biomarkers only.
Typically, early infections are considered to be associated
with acute infectious symptoms [2], but many patients
suffer exclusively from nonspecific symptoms [18]. Based
on our results, we conclude that even in early PJI non-
specific symptoms should raise the suspicion of a poten-
tially deep PJI, and further diagnostic steps, such as
arthrocentesis and synovial fluid analysis (total and white
cell count, microbiological culture), should be initiated. In
our study, the most commonly isolated microorganisms
were coagulase-negative staphylococci. Thus, based on our
results, these low-virulence microorganisms are not limited
to delayed infection.
The goal of treatment in PJI is to cure the infection,
prevent its recurrence and ensure a pain-free and func-
tional joint [19]. Despite the recently published IDSA
guidelines on PJI [7], the proposed therapeutic approach is
still under debate since many recommendations are based
on non-randomized observational studies and/or expert
opinion. There is only one randomized double blinded
prospective trial, with 33 patients demonstrating that in
early staphylococcal PJI, DAIR is a successful treatment
provided that a combination of rifampin with a fluoro-
quinolone (ciprofloxacin) is used [14]. Large cohort
studies or randomized controlled trials with high power
are still missing. In the USA, PJI is traditionally treated
with a two-stage exchange, whereas in Europe the
approach of extensive DAIR is more regularly used. DAIR
is favoured if the prosthesis is stable, the pathogen is not a
difficult-to-treat microorganism, symptoms have lasted for
\3 weeks and the skin and soft tissue are intact [2]. For a
successful debridement, mobile parts of the prosthesis
(polyethylene inlay) should be replaced [20, 21]: Choi
et al. [21] demonstrated that the lack of removal is an
independent risk factor for treatment failure. In general,
debridement and retention of the prosthesis is favoured
Fig. 1 a Kaplan–Meier curve with relapse-free survival of prosthesis
in 67 patients (69 minus 2 deaths due to sepsis) was 92.3 % (95 % CI
82.6–97) after 2 years. Dotted lines 95 % Confidence interval. b Kap-
lan–Meier curve with relapse-free survival of prosthesis in 67
patients stratified, if treatment with a debridement and retention
(n = 50) or exchange of the prosthesis (n = 17) was performed. The
relapse-free survival of the prosthesis was 91.6 % (95 % CI
79.2–96.8) for DAIR (dotted line) and 94.2 % (95 % CI
65–99.2 %) for exchange of the prosthesis after 2 years. PJI
Periprosthetic joint infection
Characteristics and treatment outcome of 69 cases 517
123
because of a lower morbidity due to a less invasive sur-
gery and reduction of cost due to a shorter hospital stay
[22]. Our study showed a successful outcome with a
prosthesis survival rate of 92 %, without a significant
difference between retention and exchange of the pros-
thesis. These findings support the result of previously
published studies—in particular the prospective random-
ized study by Zimmerli et al. [14, 23–25] in which the
outcome of early staphylococcal infections was studied.
These authors showed a 100 % treatment success with
DAIR if rifampin was combined with ciprofloxacin and no
radiological sign of loosening was detected [2]; without
the use of rifampin, treatment success was only 58 %. Our
study confirmed the good outcome of DAIR treatment
with extension to other microbial pathogens than staphy-
lococci. However, a number of studies have demonstrated
a poorer outcome with debridement and retention if the
patients were not properly selected or if a polymicrobial
infection was diagnosed [11, 12, 26].
The duration of symptoms as an important risk factor for
successful debridement and retention has been stressed in
the relevant literature [2, 8]. Taking into account the low
number of relapses in our study, we could not find any
difference between patients treated with DAIR whose
duration of symptoms was [3 or \3 weeks, respectively.
The reason for treatment failure in four patients with DAIR
was (1) suppressive treatment without rifampin from the
beginning because of non-adherence (intravenous drug use)
and liver cirrhosis, (2) intolerance to rifampin, (3)
polymicrobial infection and (4) a remaining bone sequester
after debridement. In the one patient with treatment failure
after a two-stage exchange, a screw for a fixation device
remained in situ and could not be removed, which caused
persistent infection.
The patients enrolled in our study received a long-term
antibiotic treatment, with a median duration of 3.1 or 6.1
months in the hip or knee PJI, respectively, based on
European and American guidelines [7, 27]. A total treat-
ment period of 3 months for hip PJI and 6 months for knee
PJI had been recommended earlier [2]. The authors of a
cohort study from Australia with 147 patients with early
PJI recently reported that a shortened treatment course for
\3 months is a risk factor for treatment failure [6]. How-
ever, more recently published studies favour shorter treat-
ments [28–31], but no randomized controlled trials have
been performed to date.
No consensus exists on the duration of the period of time
after surgery that defines an early infection, with current
definitions ranging from 2 weeks to 3 months [2, 3, 5–7].
In our study, no difference in outcome was seen between
patients presenting with very early (B30 days) manifesta-
tion of PJI and those presenting with early (30–90 days)
PJI manifestation. This result underlines that the
consequent use of rifampin in staphylococcal infections is
likely to be more important, as well as the choice of DAIR
as treatment option only after the proper selection of
patients with a stable prosthesis.
This study provides important epidemiological and
clinical data on early PJI and its treatment possibilities. It
especially underlines the good outcome with DAIR in a
properly selected cohort of patients and supports the data of
a previously randomized controlled study of Zimmerli
et al. [2] with extension to a variety of microbial pathogens.
The limitations of our study are its retrospective design and
the low number of patients with symptoms for[3 weeks or
early symptom onset between 30 and 90 days; this latter
limitation did not allow us to perform a risk factor analysis.
Our study cohort was heterogeneous with respect to the
different pathogens isolated and because we did not dis-
tinguish between primary and revision surgery procedures.
The latter may have led in some cases to a low-grade
infection being mistaken for an early infection after revi-
sion surgery.
In conclusion, our investigation shows that DAIR is not
inferior to two-stage exchange of the prosthesis. Therefore,
whenever possible, according to an established treatment
algorithm, early PJI should be treated with DAIR, since it
is less invasive. A high cure rate of[90 % can be reached
with DAIR provided that patients are properly selected and
an experienced multidisciplinary team of orthopaedic sur-
geons, infectious disease specialists and microbiologists
evaluates each case.
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